As we move closer to Tesla's India launch in Mumbai, automobile experts and market pundits are divided over the influence the ...

BARIPADA: A latest report by the Central Groundwater Board has pointed at high levels of fluoride contamination in several ...

That coffee machine in your office break room might be doing more than just keeping you alert during the workday.

Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.

Discover why turmeric has long been used for medicinal purposes, including for headache and migraine. Find out how it works, ...

This week's hot topics are tackled by Record Sport with plenty of terrible waterbottle related puns along the way ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Researchers predicted the likelihood of achieving target T-scores in postmenopausal women with osteoporosis who received denosumab therapy for 10 years.

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.

There are people who, without their morning coffee, cannot start the day with energy. There are also others who have a cup after every meal or more than the recommended amount. Whi ...